Intellia Therapeutics

Overview

Intellia Therapeutics advances in vivo and ex vivo CRISPR/Cas9 genome editing therapies for genetic diseases. Tailored for modern biology and life science teams.

Key Highlights

• First-in-human in vivo CRISPR therapies targeting transthyretin amyloidosis.
• Collaborations with Regeneron and Novartis on liver and hematology programs.
• Pipeline spanning autoimmune, oncology, and rare diseases.

Ideal For

• Clinicians evaluating emerging genome editing treatments
• Biotech teams partnering on CRISPR technology platforms
• Regulators and payers monitoring CRISPR clinical milestones

Quick Links

• Official site: intelliatx.com
• Add to BioDir collections to track updates and collaborators.